Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 25, 2022
Accepted: September 27, 2022
Published online: December 13, 2022

Number of Print Pages: 11
Number of Figures: 1
Number of Tables: 4

ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)

For additional information: https://www.karger.com/PPS

Abstract

Introduction: Major depressive disorder (MDD) is a highly prevalent and disabling disorder. This study examines two psychotherapy methods for MDD, behavioral activation (BA), and metacognitive therapy (MCT), when applied as outpatient treatments to severely affected patients. Methods: The study was conducted in a tertiary outpatient treatment center. Patients with a primary diagnosis of MDD (N = 122) were included in the intention-to-treat sample (55.7% female, mean age 41.9 years). Participants received one individual and one group session weekly for 6 months (M). Assessments took place at baseline, pretreatment, mid-treatment (3 M), post-treatment (6 M), and follow-up (12 M). The primary outcome was depressive symptomatology assessed by the Hamilton Rating Scale for Depression at 12 M follow-up. Secondary outcomes included general symptom severity, psychosocial functioning, and quality of life. Results: Linear mixed models indicated a change in depressive symptoms (F(2, 83.495) = 12.253, p < 0.001) but no between-group effect (F(1, 97.352) = 0.183, p = 0.670). Within-group effect sizes were medium for MCT (post-treatment: d = 0.610; follow-up: d = 0.692) and small to medium for BA (post-treatment: d = 0.636, follow-up: d = 0.326). In secondary outcomes, there were improvements (p ≤ 0.040) with medium to large within-group effect sizes (d ≥ 0.501) but no between-group effects (p ≥ 0.304). Response and remission rates did not differ between conditions at follow-up (response MCT: 12.9%, BA: 13.3%, remission MCT: 9.7%, BA: 10.0%). The deterioration rate was lower in MCT than in BA (χ21 = 5.466, p = 0.019, NTT = 7.4). Discussion: Both MCT and BA showed symptom reductions. Remission and response rates were lower than in previous studies, highlighting the need for further improvements in adapting/implementing treatments for severely affected patients with MDD.

© 2022 S. Karger AG, Basel

References IsHak WW, James DM, Mirocha J, Youssef H, Tobia G, Pi S, et al. Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016;7(3):160–9. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–46. Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210. Steffen A, Nübel J, Jacobi F, Bätzing J, Holstiege J. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. BMC Psychiatry. 2020;20:142–15. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators; Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network metaanalysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107. Cuijpers P, Karyotaki E, de Wit L, Ebert DD. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. Psychotherapy Res. 2020;30(3):279–93. Mekonen T, Chan GC, Connor JP, Hides L, Leung J. Estimating the global treatment rates for depression: a systematic review and meta-analysis. J Affect Disord. 2021;295:1234–42. Fernandez A, Haro JM, Martinez-Alonso M, Demyttenaere K, Brugha TS, Autonell J, et al. Treatment adequacy for anxiety and depressive disorders in six European countries. Br J Psychiatry. 2007;190(2):172–3. Wiegand HF, Saam J, Marschall U, Chmitorz A, Kriston L, Berger M, et al. Challenges in the transition from in-patient to out-patient treatment in depression: an analysis of administrative health care data from a large German Health Insurer. Dtsch Arztebl Int. 2020;117(27–28):472–9. Cook SC, Schwartz AC, Kaslow NJ. Evidence-based psychotherapy: advantages and challenges. Neurotherapeutics. 2017;14(3):537–45. Martell CR, Dimidjian S, Herman-Dunn R. Behavioral activation for depression: a clinician’s guide. New york: Guilford Press; 2013. Wells A. Metacognitive therapy for anxiety and depression. New York: Guilford Press; 2011. Dimidjian S, Barrera M Jr, Martell C, Muñoz RF, Lewinsohn PM. The origins and current status of behavioral activation treatments for depression. Annu Rev Clin Psychol. 2011;7:1–38. Schaich A, Heikaus L, Assmann N, Köhne S, Jauch-Chara K, Hüppe M, et al. PRO*MDD Study Protocol: effectiveness of outpatient treatment programs for major depressive disorder: metacognitive therapy vs. behavioral activation a single-center randomized clinical trial. Front Psychiatry. 2018;9:584. Stein AT, Carl E, Cuijpers P, Karyotaki E, Smits JAJ. Looking beyond depression: a meta-analysis of the effect of behavioral activation on depression, anxiety, and activation. Psychol Med. 2021;51(9):1491–504. Normann N, Morina N. The efficacy of metacognitive therapy: a systematic review and meta-analysis. Front Psychol. 2018;9:2211. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28–55. Guidi J, Brakemeier E-L, Bockting CL, Cosci F, Cuijpers P, Jarrett RB, et al. Methodological recommendations for trials of psychological interventions. Psychother Psychosom. 2018;87(5):276–84. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278–96. Carrozzino D, Patierno C, Fava GA, Guidi J. The Hamilton rating scales for depression: a critical review of clinimetric properties of different versions. Psychother Psychosom. 2020;89(3):133–50. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82. Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J affective Disord. 2004;81(1):61–6. Franke GH, Derogatis LR. Brief symptom inventory: BSI; (Kurzform der SCL-90-R). Weinheim, Germany: Beltz Test; 2000. Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the World Health Organization disability assessment schedule 2.0. Bull World Health Organ. 2010;88(11):815–23. Salyers MP, Bosworth HB, Swanson JW, Lamb-Pagone J, Osher FC. Reliability and validity of the SF-12 health survey among people with severe mental illness. Med Care. 2000;38(11):1141–50. Boulet J, Boss MW. Reliability and validity of the brief symptom inventory. Psychol Assess. 1991;3(3):433–7. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–86. Kroenke K, Spitzer R, Williams J. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606–13. Wittchen H-U, Wunderlich U, Gruschwitz S, Zaudig M. SKID I. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Interviewheft und Beurteilungsheft. Eine deutschsprachige, erweiterte Bearb. d amerikanischen Originalversion des SKID I. 1997. Wittchen H-U, Zaudig M, Fydrich T. Skid. Strukturiertes klinisches Interview für DSM-IV. Achse I und II. Handanweisung. 1997. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Virginia, USA: American Psychiatric Pub; 2013. Fassbinder E. Therapie-tools depression. Weinheim, Germany: Beltz; 2015. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123–4. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–9. Rezvan PH, Lee KJ, Simpson JA. The rise of multiple imputation: a review of the reporting and implementation of the method in medical research. BMC Med Res Methodol. 2015;15(1):1–14. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 2013. Wampold BE, Mondin GW, Moody M, Stich F, Benson K, Ahn HN. A meta-analysis of outcome studies comparing bona fide psychotherapies: empiricially, “all must have prizes”. Psychol Bull. 1997;122(3):203–15. Luborsky L, Rosenthal R, Diguer L, Andrusyna TP, Berman JS, Levitt JT, et al. The dodo bird verdict is alive and well: mostly. Clin Psychol Sci Pract. 2002;9(1):2–12. Budd R, Hughes I. The Dodo Bird Verdict: controversial, inevitable and important: a commentary on 30 years of meta-analyses. Clin Psychol Psychother. 2009;16(6):510–22. Cuijpers P, Reijnders M, Huibers MJ. The role of common factors in psychotherapy outcomes. Annu Rev Clin Psychol. 2019;15(1):207–31. de Felice G, Giuliani A, Halfon S, Andreassi S, Paoloni G, Orsucci FF. The misleading Dodo Bird verdict. How much of the outcome variance is explained by common and specific factors? New Ideas Psychol. 2019;54:50–5. Borsboom D. A network theory of mental disorders. World Psychiatry. 2017;16(1):5–13. Contreras A, Nieto I, Valiente C, Espinosa R, Vazquez C. The study of psychopathology from the network analysis perspective: a systematic review. Psychother Psychosom. 2019;88(2):71–83. Janssen NP, Hendriks G-J, Baranelli CT, Lucassen P, Oude Voshaar R, Spijker J. How does behavioural activation work? A systematic review of the evidence on potential mediators. Psychother Psychosom. 2021;90(2):85–93. Ekers D, Webster L, Van Straten A, Cuijpers P, Richards D, Gilbody S. Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis. PLoS One. 2014;9(6):e100100. Brakemeier E-L, Radtke M, Engel V, Zimmermann J, Tuschen-Caffier B, Hautzinger M, et al. Overcoming treatment resistance in chronic depression: a pilot study on outcome and feasibility of the cognitive behavioral analysis system of psychotherapy as an inpatient treatment program. Psychother Psychosom. 2015;84(1):51–6. Schramm E, Kriston L, Zobel I, Bailer J, Wambach K, Backenstrass M, et al. Effect of disorder-specific vs nonspecific psychotherapy for chronic depression: a randomized clinical trial. JAMA Psychiatry. 2017;74(3):233–42. Sürig S, Ohm K, Grave U, Glanert S, Herzog P, Fassbinder E, et al. Change in interpersonal and metacognitive skills during treatment with cognitive behavioral analysis system of psychotherapy and metacognitive therapy: results from an observational study. Front Psychiatry. 2021;12:619674. Guidi J, Fava GA, Fava M, Papakostas GI. Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis. Psychol Med. 2011;41(2):321–31. Fava GA, Rafanelli C. Iatrogenic factors in psychopathology. Psychother Psychosom. 2019;88(3):129–40. Buckman JEJ, Saunders R, Stott J, Cohen ZD, Arundell L-L, Eley TC, et al. Socioeconomic indicators of treatment prognosis for adults with depression: a systematic review and individual patient data meta-analysis. JAMA Psychiatry. 2022;79(5):406. Article / Publication Details

First-Page Preview

Received: May 25, 2022
Accepted: September 27, 2022
Published online: December 13, 2022

Number of Print Pages: 11
Number of Figures: 1
Number of Tables: 4

ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)

For additional information: https://www.karger.com/PPS